Limitations, agreements, and source contact

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia · Source last updated 2020-08-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

tom.chmielewski@jazzpharma.com

organization

Jazz Pharmaceuticals

phone

2158709177

title

Associate Director, Clinical Trial Disclosure & Transparency

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice